Guaraná

Overview

Guaraná is the seed of Paullinia cupana, an Amazonian climbing plant native to Brazil, valued for one of the highest natural caffeine contents of any plant alongside a procyanidin/catechin polyphenol matrix. Mechanistically, its caffeine antagonizes A1/A2A adenosine receptors and inhibits phosphodiesterase, while the polyphenol complex is proposed to slow caffeine release and add antioxidant activity. Research-context dosing ranges from 37.5-300 mg full-spectrum extract for acute cognition, 50-75 mg/day standardized extract in cancer-fatigue trials, and ~200-500 mg pre-exercise, with traditional Brazilian use of 0.5-2 g/day seed powder. Regulatory status is a lawful dietary-supplement and GRAS caffeine source in the US, a non-Novel food supplement in the EU (no guarana-specific health claim), and a fully established traditional ingredient in Brazil under ANVISA; total caffeine must stay under 400 mg/day for adults (200 mg/day in pregnancy) and concentrated extract is not for children.

Mechanism of Action

Caffeine antagonizes A1/A2A adenosine receptors, reducing the sleep-promoting / fatigue signaling that lowers alertness (research-context mechanism) · Phosphodiesterase inhibition by methylxanthines (caffeine, theobromine, theophylline) raising intracellular cAMP (mechanistic) · Polyphenol matrix (procyanidins B1-B4, catechin, epicatechin) forms a slow-release complex with caffeine, proposed to flatten the peak-and-crash curve seen with isolated caffeine (mechanism / pharmacokinetic hypothesis) · Free-radical scavenging / antioxidant activity of catechins and procyanidins in mechanistic and ex-vivo work (e.g., reduced LDL oxidation) · Promotion of fat oxidation and thermogenesis, studied mainly in caffeine + green-tea co-formulations (research-context) · Platelet-aggregation inhibition and MAO modulation reported in preclinical / mechanistic studies

Body systems: Neurological & Cognitive · Mood & Stress Response · Musculoskeletal · Cardiovascular · Endocrine & Metabolic · Immune System

Evidence-Based Benefits

Dosage (research context · not a recommendation)

Research-context dosing varies by endpoint and form. Cancer-related fatigue RCTs used 50-75 mg/day of standardized purified dry extract (PC-18 / ~22% caffeine; ≈11-16 mg caffeine) over ~21 days. Acute cognitive RCTs used 37.5-300 mg full-spectrum extract (≈8-66 mg caffeine), where low doses were as or more effective than high doses — suggesting a non-caffeine (procyanidin/catechin) contribution. Thermogenesis/weight studies used 200-400 mg/day, usually combined with green tea. Cycling-performance RCTs used ~200-300 mg pre-exercise. Traditional Brazilian use is 0.5-2 g/day seed powder brewed in water. Total caffeine from ALL sources should stay <400 mg/day (adults) / <200 mg/day (pregnancy) — guarana carries 2-3x the caffeine of coffee beans, so the dose must always be converted to total caffeine. Educational reference only, not a dosing recommendation.

Regulatory Status · 4 Markets

US · FDA

Lawful dietary-supplement ingredient under DSHEA (pre-DSHEA use history — marketed in the US before 1994, so no NDI notification required) and a self-affirmed GRAS natural caffeine source for food/beverage use; never 'FDA approved'. Structure/function claims only, with the mandatory DSHEA disclaimer and 30-day FDA notification. No disease claims. FDA warning-letter precedent against marketing high-caffeine products to children.

EU · EFSA

Traditional food ingredient, NOT a Novel Food (long EU use history); Paullinia cupana seed is on the BELFRIT (Belgium-France-Italy) botanical list and is marketable as a food supplement under Directive 2002/46/EC (member-state botanical lists vary). Guarana itself has NO authorized Article 13/14 health claim. However, products delivering ≥75 mg caffeine per serving may use the EFSA-authorized caffeine claims ('Caffeine contributes to increased alertness' / 'to an increase in endurance performance'). Beverages with caffeine ≥150 mg/L must carry the 'High caffeine content. Not recommended for children or pregnant or breast-feeding women' label (Reg (EU) 1169/2011). EFSA 2015 caffeine safe upper limit: 400 mg/day adults, 200 mg/day pregnancy.

BR · ANVISA

Fully established in Brazil (origin country): a traditional food ingredient and an authorized dietary-supplement constituent under RDC 243/2018 + IN 28/2018 (Paullinia cupana seed), and a Traditional Herbal Product under RDC 240/2018 Annex I. Dietary-supplement caffeine cap is 420 mg per daily serving (all sources). Mandatory caffeine-content labeling plus the warning 'Contém cafeína. Não recomendado para crianças, gestantes, lactantes e pessoas sensíveis à cafeína'. Traditional-use claims only (no disease claims). No Anexo V functional health claim specific to guarana. [China NMPA, for reference: not approved — absent from novel-food, health-food, and medicine-food-homology lists; only compliant C-end channel is cross-border e-commerce with no functional claims and mandatory caffeine declaration on the Chinese label.]

Safety

Generally well tolerated within studied ranges; decades of population-level consumption in Brazil (Guaraná Antarctica is the country's #2 soft-drink brand). Adverse effects are caffeine-mediated — insomnia, palpitations, jitteriness, GI upset — and become more likely at high extract doses (>500 mg/day). Two HARD safety limits apply across markets: (1) total caffeine <400 mg/day for adults and <200 mg/day in pregnancy (FDA/EFSA/Health Canada/ACOG consensus); products must convert the guarana dose to total caffeine and disclose it; (2) concentrated guarana extract is contraindicated in children (<18). Caution in hypertension, arrhythmia, and cardiovascular disease (additive stimulant risk). Documented interactions: MAO inhibitors, other CNS stimulants, warfarin/CYP1A2 substrates, and lithium (caffeine diuresis can affect lithium levels) — all caffeine-mediated. Stacking with coffee, tea, energy drinks, or cola can exceed the daily caffeine ceiling. Not for pregnant/breastfeeding women without medical guidance.

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

1. PMID 34146166 · de Araujo 2021 · Support Care Cancer — Cancer-related fatigue (pooled evidence)
2. PMID 19388866 · Miranda 2009 · J Altern Complement Med — Post-radiation fatigue & depression (breast cancer RCT)
3. PMID 27322597 · Martins 2017 · J Diet Suppl — Chemoradiotherapy fatigue & quality of life (head & neck RCT)
4. PMID 36678305 · Hack 2023 · Nutrients — Acute cognitive performance (response time)
5. PMID 37898479 · Penna 2023 · Int J Sport Nutr Exerc Metab — Cycling time-trial performance

Frequently Asked Questions